Atellica IM CA 19-9 II

FDA 510(k) K253528 · Siemens Healthcare Diagnostics, Inc.

Substantially Equivalent

510(k) numberK253528

Submission

Device name
Atellica IM CA 19-9 II
Applicant
Siemens Healthcare Diagnostics, Inc.
Tarrytown, NY, US
Received
November 13, 2025
Decision date
August 10, 2026
Decision
Substantially Equivalent (SESE)
Type
Traditional 510(k)
Summary
510(k) summary available from FDA

Official FDA 510(k) record

Device classification

Product code
NIG – System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer
Device class
Class II (moderate risk)
Regulation
21 CFR 866.6010
Specialty
Immunology

An in vitro diagnostic test for the quantitative measurement of the CA 19-9 tumor associated antigen in human serum or plasma. The test is intended as an aid in the management of patients with confirmed pancreatic cancer and serial monitoring of their response to therapy and disease progression. The test should only be used in patients with serum and plasma CA 19-9 values above the cut-off at…

Other 510(k)s with product code NIG

510(k)DeviceApplicantDecision
K231525VITROS Immunodiagnostic Products CA 19-9TM Reagent PackNIG · Traditional Ortho Clinical Diagnostics08/09/2023SE
K200997Lumipulse G CA19-9-NNIG · Special Fujirebio Diagnostics,Inc.05/14/2020SE
K191973Lumpipulse G CA19-9-NNIG · Traditional Fujirebio Dianostics, Inc.10/22/2019SE
K100375Dimension Vista Loci Ca 19-9 Flex Reagent Cartridge, and Dimension LOCI7 Calibrator with…NIG · Traditional Siemens Healthcare Diagnostics, Inc.04/06/2011SE
K052889Vitros Ca 19-9NIG · Traditional Fujirebio Diagnostics,Inc.12/20/2005SE
K052000Architect Ca 19-9XR AssayNIG · Traditional Fujirebio Diagnostics,Inc.10/25/2005SE
K033038Gi Monitor and Gi Monitor Calibrators on the Access Immunoassay Systems, Model 387687…NIG · Traditional Beckman Coulter, Inc.12/29/2003SE
K031393Bayer Advia Centaur Ca 19-9 AssayNIG · Traditional Bayer Healthcare, LLC06/24/2003SE
K023240ST Aia-Pack Ca 19-9NIG · Traditional Tosoh Corp.12/23/2002SE
K023239Aia-Pack Ca 19-9NIG · Traditional Tosoh Corp.12/23/2002SE

More from Tosoh Corp.

510(k)DeviceDecision
K261364Atellica CH Acetaminophen 2 (ACTM)LDP · Traditional 07/24/2026SE
K251998Atellica CH Diazo Total Bilirubin (D_TBil)CIG · Traditional 02/27/2026SE
K251543Atellica® IM TSH3-Ultra II (TSH3ULII)JLW · Traditional 02/06/2026SE
K251630Atellica IM Total PSA II (tPSAII)LTJ · Traditional 01/05/2026SE
K250816ADVIA Centaur Anti-Thyroglobulin II (aTgII)JNL · Traditional 12/04/2025SE
K250250ADVIA Centaur Anti-Thyroid Peroxidase IIJZO · Traditional 10/17/2025SE
K242981Atellica IM Thyroglobulin (Tg)MSW · Traditional 06/20/2025SE
K243570Dimension LOCI Thyroid Stimulating Hormone Flex reagent cartridge (TSHL); Dimension LOCI…JLW · Traditional 04/25/2025SE
K242685Atellica® CH Creatinine_3 (Crea3)CGX · Traditional 12/04/2024SE
K241800Atellica® CH HDL Cholesterol (HDLC)& Atellica® CH LDL Cholesterol (LDLC)MRR · Traditional 07/26/2024SE

Questions and answers

When was Atellica IM CA 19-9 II cleared by the FDA?

Atellica IM CA 19-9 II (K253528) received a 510(k) decision of Substantially Equivalent on August 10, 2026, 270 days after the submission was received.

What is the product code of K253528?

The FDA product code is NIG – System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer, a Class II (moderate risk) device regulated under 21 CFR 866.6010.